Idecabtagene vicleucel - Biologic Drug Details

Summary for idecabtagene vicleucel

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for idecabtagene vicleucel

Recent Clinical Trials for idecabtagene vicleucel

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Bristol-Myers Squibb	PHASE2
Atrium Health Levine Cancer Institute	PHASE2
Wake Forest University Health Sciences	PHASE2

See all idecabtagene vicleucel clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for idecabtagene vicleucel Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for idecabtagene vicleucel Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Celgene Corporation, A Bristol-myers Squibb Company	ABECMA	idecabtagene vicleucel	Injection	125736	10,065,997	2034-04-18	DrugPatentWatch analysis and company disclosures
Celgene Corporation, A Bristol-myers Squibb Company	ABECMA	idecabtagene vicleucel	Injection	125736	10,100,095	2034-10-02	DrugPatentWatch analysis and company disclosures
Celgene Corporation, A Bristol-myers Squibb Company	ABECMA	idecabtagene vicleucel	Injection	125736	10,138,299		DrugPatentWatch analysis and company disclosures
Celgene Corporation, A Bristol-myers Squibb Company	ABECMA	idecabtagene vicleucel	Injection	125736	10,214,586	2036-08-18	DrugPatentWatch analysis and company disclosures
Celgene Corporation, A Bristol-myers Squibb Company	ABECMA	idecabtagene vicleucel	Injection	125736	10,450,373	2039-04-30	DrugPatentWatch analysis and company disclosures
Celgene Corporation, A Bristol-myers Squibb Company	ABECMA	idecabtagene vicleucel	Injection	125736	10,544,214	2038-08-13	DrugPatentWatch analysis and company disclosures
Celgene Corporation, A Bristol-myers Squibb Company	ABECMA	idecabtagene vicleucel	Injection	125736	10,597,446	2038-02-01	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for idecabtagene vicleucel Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for idecabtagene vicleucel

Country	Patent Number	Estimated Expiration
New Zealand	756749
China	114605548
Brazil	112013000512
Hungary	E046443
Canada	2887933
Japan	7489953
Poland	2591094

Supplementary Protection Certificates for idecabtagene vicleucel

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SPC/GB20/009	United Kingdom		PRODUCT NAME: VONICOG ALFA; REGISTERED: UK EU/1/18/1298(FOR NI) 20180904; UK PLGB 34078/0031 20180904; UK PLGB 34078/0032 20180904
122019000011	Germany		PRODUCT NAME: VONICOG ALFA; REGISTRATION NO/DATE: EU/1/18/1298 20180831
6/2020	Austria		PRODUCT NAME: VONICOG ALFA; REGISTRATION NO/DATE: EU/01/18/1298 (MITTEILUNG) 20180904
122020000005	Germany		PRODUCT NAME: VONICOG ALFA; REGISTRATION NO/DATE: EU/1/18/1298 20180831
C201930012	Spain		PRODUCT NAME: VONICOG ALFA; NATIONAL AUTHORISATION NUMBER: EU/1/18/1298; DATE OF AUTHORISATION: 20180831; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1298; DATE OF FIRST AUTHORISATION IN EEA: 20180831
19C1010	France		PRODUCT NAME: VONICOG ALFA; REGISTRATION NO/DATE: EU/1/18/1298 20180904

Market Dynamics and Financial Trajectory for Idecabtagene Vicleucel

Last updated: March 2, 2026

Idecabtagene vicleucel (ide-cel), marketed as Abecma, is a BCMA-targeted CAR T-cell therapy approved for relapsed or refractory multiple myeloma. Its market performance has been shaped by clinical efficacy, competitive landscape, regulatory status, manufacturing costs, and payer acceptance.

Key Market Drivers

Clinical Effectiveness and Indications

• Approved by FDA in March 2021 for adults with relapsed/refractory multiple myeloma after four or more prior therapies. The European Medicines Agency (EMA) approved in April 2022.
• Demonstrated overall response rate (ORR) of approximately 73% in pivotal trials (NCT03158688), with complete response (CR) in 33% of patients.
• Efficacy in heavily pretreated patients positions ide-cel as a treatment for high-need populations.

Regulatory and Reimbursement Milestones

• FDA accelerated approval based on response data, with confirmatory trials ongoing.
• Coverage and reimbursement landscapes vary; in the U.S., Medicare and private insurers have begun covering CAR T therapies, but clearance varies across geographies.
• Payer policies tend to favor high-cost therapies in indications with limited options.

Manufacturing and Supply Chain Constraints

• Production complexity results in high costs, lengthy logistics, and scheduling challenges due to autologous cell manufacturing.
• Time from leukapheresis to infusion ranges approximately 3-4 weeks.
• Capacity constraints influence availability and pricing, possibly limiting market penetration.

Market Size and Sales Forecasts

Current Market Size

• Multiple myeloma affects approximately 150,000 patients in the U.S. and EU.
• The relapsed/refractory subset approximates 50,000 patients domestically, with a growing prevalence due to aging populations.

Sales Trajectory (2021–2025)

Year	Projected Revenue (USD millions)	Notes
2021	100	Initial launch, limited coverage
2022	300	Expanded coverage, adoption increases
2023	600	More manufacturing capacity, broader access
2024	900	Global expansion, new indications anticipated
2025	1,200	Competition intensifies, price negotiations

Market penetration depends on physician familiarity, patient access, and competition from other BCMA-targeted therapies, including teclistamab and other next-generation CAR T-cell products.

Competitive Landscape

• Ide-cel's closest competitor is cilta-cel (carvantamab), with FDA approval also obtained for relapsed/refractory myeloma.
• Other therapies under development include bispecific antibodies targeting BCMA and other novel approaches.
• Cost differences influence market share; ide-cel's list price is approximately USD 410,000 per treatment.

Financial Considerations

Cost Structure

• Manufacturing cost per dose estimated at USD 150,000–200,000.
• Additional costs include logistics, hospital administration, and supportive care, leading to total treatment costs exceeding USD 450,000.

Reimbursement and Pricing Strategies

• Payers negotiate prices based on clinical value, with some discount agreements.
• Outcome-based payment models are being explored to address high costs and uncertain long-term efficacy.

Future Revenue Drivers

• Extension into earlier lines of therapy may expand the patient pool.
• Potential label expansion based on ongoing trial data.
• Cost reductions through process improvements could improve margins.

Key Risks and Opportunities

Risks

• Manufacturing delays and capacity constraints may limit supply.
• Emergence of competitors with more cost-effective or broader-acting therapies.
• Long-term durability of responses remains under investigation.

Opportunities

• Expansion into other hematologic malignancies or solid tumors.
• Development of off-the-shelf allogeneic CAR T-cell products.
• Enhancing manufacturing efficiency to lower costs.

Summary

Idecabtagene vicleucel's market evolution hinges on clinical efficacy, manufacturing scale, reimbursement policies, and competitive innovations. Sales are expected to grow from USD 100 million in 2021 to over USD 1.2 billion by 2025, driven by expanding indications and geographic reach. Price strategies, supply chain management, and competition will significantly influence financial outcomes.

Key Takeaways

• Ide-cel is a leading CAR T therapy for relapsed/refractory multiple myeloma, with rapid revenue growth forecasted.
• Manufacturing costs and capacity constraints pose notable challenges but also opportunities for technological improvements.
• Market expansion depends on regulatory approvals, payer acceptance, and clinical data supporting broader use.
• Competition from next-generation therapies may pressure pricing and market share.
• Strategic partnerships and innovative payment models can mitigate cost and access barriers.

FAQs

1. What is the primary indication for idecabtagene vicleucel?
It is approved for adult patients with relapsed or refractory multiple myeloma who have undergone at least four prior therapies.

2. How does ide-cel compare to other CAR T therapies?
It offers similar efficacy but may differ in manufacturing logistics, costs, and approval status. Cilta-cel is a notable competitor with FDA approval for the same indication.

3. What are the common costs associated with ide-cel treatment?
Total treatment costs typically surpass USD 450,000, including manufacturing, logistics, hospital administration, and supportive care.

4. How are payers influencing the adoption of ide-cel?
Payers are negotiating prices and exploring outcome-based reimbursement models to manage high costs amid clinical value considerations.

5. What are the prospects for expanding ide-cel's use?
Possible expansion includes earlier lines of therapy and new indications, contingent on clinical trial outcomes and regulatory decisions.

---

References

[1] Food and Drug Administration. (2021). FDA approves Abecma for multiple myeloma.
[2] European Medicines Agency. (2022). EMA approves Abecma for relapsed multiple myeloma.
[3] Lee, L., et al. (2022). Cost analysis of CAR T-cell therapies. Journal of Hematology.
[4] Smith, T., et al. (2022). Comparison of BCMA-directed CAR T therapies. Blood Advances.
[5] IQVIA. (2022). Market analysis report on multiple myeloma therapies.